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ABSTRACT
CHARACTERATION OF THE ACTIVATION AND ALLOSTERIC REGULATION 
OF PHOTORECEPTOR PHOSPHODIESTERASE (PDE6)
by
Yu-Ting Liu 
University of New Hampshire, September, 2007 
Photoreceptor phosphodiesterase (PDE6) amplifies visual signals in rod and cone 
photoreceptors. We developed an assay to quantify binding of radiolabeled PDE inhibitors to the 
catalytic sites of PDE6 to explore the activation and regulation of PDE6. We determined that both 
catalytic domains on the PDE6 heterodimer are catalytically active and equivalent. Only one 
catalytic subunit on PDE6 readily binds to and becomes activated by the G-protein, transducin. 
The other PDE6 catalytic site requires a large excess of activated transducin to fully activate 
PDE6. We conclude that transducin activates the two catalytic subunits of rod PDE6 differently. 
We also demonstrated direct allosteric communication between the regulatory GAF domain and 
catalytic domain of PDE6: binding of a fragment of the inhibitory gamma subunit to the GAF 
domain stabilized radiolabeled PDE inhibitor binding to the catalytic sites; conversely, occupancy 
of the catalytic site by PDE inhibitors altered cGMP binding to the GAF domain.
xii




Cyclic nucleotide phosphodiesterases (PDEs) are enzymes that regulate the 
cellular levels of the second messengers, cAMP and cGMP. There are 11 different 
vertebrate PDE families (Beavo et al., 2006), with each family typically having several 
different isoforms and splice variants (Table 1.1). These distinct PDE families differ in 
their amino acid sequences, kinetic properties, modes of regulation, intracellular 
localization, cellular expression and inhibitor sensitivities.
A l. Rod and Cone Photoreceptor PDE6
Photoreceptor phosphodiesterase (PDE6) is the central effector enzyme in 
phototransduction in rod and cone photoreceptor cells. PDE6 is unique among PDE 
families for its regulation by a G-protein, transducin, for its isoprenylated C-terminus 
which attaches to the disk membrane, and for the regulation of its catalytic activity by 
inhibitory y-subunits (Py). Few differences between rod and cone PDE6 have been 
reported. Rod PDE6 is a tetramer, in which two Py tightly bind to non-identical a and 6 
catalytic subunits (Pah) (Baehr et al., 1979; Deterre et al., 1988). In contrast, cone PDE6 
contains two identical a ’ catalytic subunits which are highly homologous to the rod a and
1
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P subunits. The cone y’-subunit (Py’) is 3 amino acids smaller than rod Py but the amino 









PDE1 3 dual heart, brain, muscle, etc. vinpocetine
PDE2 1 dual adrenal, heart, lung, etc. EHNA








































Table 1.1 Phosphodiesterase Superfamily. The Phosphodiesterase (PDE) superfamily 
contains 11 distinct members that degrade cellular second messenger cAMP and cGMP. 
The table contains the number of genes encoded each PDE, the substrate selectivity 
toward cAMP or cGMP, the existence in certain tissues, and the specific inhibitors 
reported for each family member to date. Inhibitors in parentheses are ones that should be 
considered PDE5/6 selective inhibitors. The information complied from (Beavo et al., 
2006).
2
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PDE6 regulation by Py is essential for operation of the phototransduction cascade. 
Bovine rod PDE6 catalytic subunits contain two non-identical Py binding sites, both of 
which bind with very high affinity (Mou and Cote, 2001). Rod PDE6 has a higher affinity 
for Py than cone PDE6 does for its corresponding Py’ (Hamilton et al., 1993).
Because the physiological responses of rods and cones to light differ greatly in 
their sensitivity, kinetics and adaptation properties, it is reasonable to hypothesize that 
some of these differences might be due to differences in the biochemical and/or 
regulatory properties of rod and cone PDE6. Prior studies of the enzymological properties 
of PDE6 indicated that they share similar kinetic properties [KM and kcat have been 
reported in rod and cone PDE6 (Gillespie and Beavo, 1988; Huang et al., 2004; Mou and 
Cote, 2001; Valeriani, 2004)]. However, most enzymatic studies have been focused on 
rod PDE6 [bovine kcat= 5440 s '1; frog kcat= 7500 s’1; (Norton et al., 2000; Mou and Cote, 
2001)]. The results for cone PDE6 vary. For example, cone PDE6 kcat has been reported 
to range from 3500~5600 s’1 (Granovsky et al., 1998; Gillespie and Beavo, 1988; 
Valeriani, 2004).
The Py concentration is equal to PDE6 catalytic subunits in rod outer segments 
(Norton et al., 2000). In the dark-adapted state, almost all PDE6 exists as the non­
activated holoenzyme (Pa(3yy) by the binding of Py to PaP with very high affinity 
(Wensel and Stryer, 1986). The basal activity of rod PDE6 is equivalent to only 1 out of 
2200 PaP being fully active [i.e., lacking Py (Rieke and Baylor, 1996; D'Amours and 
Cote, 1999)]. Removing Py from the catalytic dimer by limited proteolysis (Hurley and 
Stryer, 1982), by competition with polycationic proteins (Miki et al., 1975), or by 
extraction of Py by binding to activated transducin (Yamazaki et al., 1983) relieves Py
3
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inhibition and stimulates catalysis. The catalytic mechanism of PDE6 that involves 
transducin is not well understood at the molecular level. Chapter 2 presents experiments 
to explore how activated transducin causes PDE6 activation.
Studies on PDE6 inhibition by various classes of PDE6 inhibitors showed that 
inhibitors studied to date poorly discriminate rod and cone PDE6 (Gillespie and Beavo, 
1989b; D'Amours et al., 1999; Zhang et al., 2005). Thus, further work is needed to 
examine the pharmacological properties of rod and cone PDE6 to determine whether 
differences in the active site can be discovered. Experiments described in Chapter 3 
address this issue, which is of importance in evaluating whether difference in rod and 
cone PDE6 can account for differences in rod and cone cell light responses.
A2. Catalytic Subunits of PDE6
PDE6 catalytic subunits consist of a heterodimer of a and B subunits (Figure 1.1). 
Each catalytic subunit has a catalytic domain (similar in all 11 PDE families) attached to 
an N-terminal regulatory domain comprised of two tandem GAF domains (GAFa and 
GAFb) (Cote, 2006). In addition, a C-terminal isoprenylation motif allows the enzyme to 
be tethered to the photoreceptor disk membrane by famesyl and geranylgeranyl groups 
(Figure 1.2) (Anant et al., 1992; Qin et al., 1992).
4
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Figure 1.1 The Molecular Organization of PDE6. The organization of catalytic 
domains and two tandem GAF domains of rod PDE6 catalytic subunits is depicted as a 3- 
D model analyzed by electron microscopy (Kameni Tcheudji et al., 2001). The Py 
subunits could not be visualized at this level of resolution.
PDE6 catalytic subunit











Figure 1.2 Domain Organization of the Catalytic Subunits of PDE6. The catalytic 
subunit of PDE6 consists of regulatory GAFa and GAFb domains, a catalytic domain, 
and a prenylated C-terminus. The noncatalytic cGMP binding and the N-terminal Py 
binding interaction sites are within GAFa domains and the GAFa domain also serves as 
the main functional site for dimerization. Metal ion binding within the catalytic site is 
critical for catalysis. The C-terminal region of Py binds to the catalytic site to inhibits the 
catalysis of PDE6.
5
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A2a. Catalytic Domain of PDE6
The catalytic domain of PDE6 is comprised of approximately 280 amino acid 
residues located in the C-terminal part of the molecule and is highly conserved among all 
known PDE families (Cote, 2006). Because of the difficulty in expressing functional 
PDE6 catalytic subunits in heterologous systems (Granovsky et al., 1998; Muradov et al., 
2006), no crystal structure or site-directed mutagenesis of PDE6 has been reported. The 
constructed chimeric protein containing both PDE5 and PDE6 sequences with structural 
homology modeling was studied for understanding the structure of the PDE6 catalytic 
domain. Activated rod PDE6 catalytic dimer has a ~1000-fold higher turnover number 
for cGMP than for the closely related PDE5 family. The basis for this difference is not 
entirely understood, but is likely due in part to differences of the metal-binding pocket of 
the active site of the two enzyme families. In one study, the kcat was increased 10-fold 
when substituting two PDE5 residues for their PDE6 counterparts in the active site near 
the metal binding site (Granovsky and Artemyev, 2001). The histidine residues which 
bind zinc and magnesium in the active site of PDE6 are likely to be homologous to 
similar residues in the active site of PDE5 (Francis et al., 2000). Binding of divalent 
cations is critically important for both hydrolytic activity and enzyme stability of PDE6 
(He et al., 2000). The presence of a “glutamine switch” in PDE6 likely confers substrate 
specificity for cGMP over cAMP (Zhang et al., 2004).
A2b. GAF Domains
The N-terminal half of the PDE6 catalytic subunits contains two structural motifs 
called GAF domains (GAFa and GAFb) because of their presence in cGMP-regulated
6
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PDE, adenylate cyclases, and the E. coli protein FhlA (Aravind and Ponting, 1997). The 
tandem GAF domains of PDE6 are highly conserved in amino acid sequence within the 
PDE6 family, as well as showing strong sequence similarity to the other four GAF- 
containing PDE families (PDE2, PDE5, PDE10, and PDE11). For PDE2, PDE5 and 
PDE6, binding of cGMP to the regulatory GAF domains has been demonstrated 
experimentally (Gillespie and Beavo, 1989a; Martins et al., 1982; Thomas et al., 1990; 
Yamazaki et al., 1982). Noncatalytic cGMP binding has been shown to directly stimulate 
the catalytic activity of PDE2 and PDE5 (Martins et al., 1982; Rybalkin et al., 2003). The 
functional significance of the GAF domains of PDE6 is not well understood. In PDE6, 
cGMP binding to regulatory GAF domains enhances the affinity of the inhibitory Py 
subunits for the catalytic subunits, but does not appear to influence the catalytic activity 
independent of Py binding. Reciprocally, Py binding enhances the affinity of cGMP 
binding to the GAF domains (Cote et al., 1994; Mou and Cote, 2001).
Determination of the crystal structure of PDE2A GAFa-GAFb domains with 
cGMP bound revealed that the cGMP binding site lies within the PDE2 GAFb domain 
(Martinez et al., 2002). Furthermore, the residues stabilizing cGMP binding represent a 
novel cGMP binding motif. Sequence comparison of PDE2, PDE5 and PDE6 predict that 
the GAFa—rather than GAFb—domain is the likely site for cGMP binding in both PDE5 
and PDE6 (Martinez et al., 2002). This prediction has been confirmed for PDE5 (Liu et 
al., 2002; Sopory et al., 2003) and PDE6 (Huang et al., 2004; Muradov et al., 2004) 
through the identification of several amino acid residues important for high-affinity 
interactions with cGMP. Specifically, several residues essential for stabilizing high-
7
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affinity cGMP binding to PDE6 were only found within or close to the H4 helix in 
cGMP-binding PDEs (Huang et al., 2004; Muradov et al., 2004).
The structural model of the PDE6 holoenzyme (Figure 1.1) suggests that the 
GAFa domains on the catalytic subunits of rod and cone PDE6 also contain the 
dimerization sites which are critical for forming tightly bound catalytic dimers (Kameni 
Tcheudji et al., 2001). A mutagenesis study in the N-terminal region of the GAFa domain 
confirmed this function and also pointed out that the formation of aB catalytic 
heterodimer is strongly selected over aa or BB formation (Muradov et al., 2003). This 
work also supported early reports of rod heterodimer formation (Artemyev et al., 1996b).
There are also interaction sites within the GAFa domain which bind to the N- 
terminal inhibitory Py subunits of PDE6 (see section A3 below). The binding of Py to the 
two GAFa domains on the PDE6 catalytic dimer is non-identical, as is also true for 
noncatalytic cGMP binding, and this heterogeneity suggests structural differences of the 
GAFa domains of the a-subunit and 6-subunit (Guo et al., 2005).
Unlike well discovered GAFa domain, the function of GAFb domain remains 
unclear. The GAFb domain of PDE6 contains a 29-amino acid sequence inserted in its 
signature residues (NFKDE) that is absent in the GAFa domain sequence; this GAFb 
insert may impair cGMP binding at this site. A mutagenesis study determined that an 
asparagine residue in the PDE6 GAFb domain is critical for cGMP binding. This result 
may be due to indirect stabilization of cGMP binding in GAFa domain by conformational 
change of the GAFb domain (Granovsky et al., 1998). Although there is no evidence 
regarding the role of GAFb, it is possible that GAFb helps stabilize the formation of the 
PaB catalytic dimer (Muradov et al., 2003).
8
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A3. Inhibitory Subiinits
PDE6 is unique among the PDE families in having its catalytic activity regulated 
by its inhibitory Py subunit. Two regions of Py are primarily involved in its interaction 
with PDE6 catalytic subunits (Figure 1.3), the central polycationic region (residues 21-45 
of rod Py) and the Py C-terminus. The polycationic region makes a major contribution to 
the overall affinity of Py for PDE6 catalytic subunits (Artemyev and Hamm, 1992; Mou 
and Cote, 2001). A cross-linking study using a photoexcitable peptide probe 
corresponding to the polycationic region of Py revealed incorporation of the probe into 
the GAFa domain of rod Pa at residues Met138Gly139 (Muradov et al., 2002). In addition, 
mutagenesis of PDE6-specific amino acids in the vicinity of this site can abolish binding 
of Py to the catalytic dimer (Muradov et al., 2004).
The C-terminus of Py represents the key inhibitory domain and apparently 
directly occludes the catalytic cavity (Granovsky et al., 2000). By direct binding of its C- 
terminal residue to the catalytic pocket, Py blocks the access of cGMP binding to the 
catalytic sites of PDE6 (Artemyev et al., 1996a; Granovsky et al., 1997).
PDE6 inhibitory subunit
|p -r i t ;h  |  P C  r e y i o T T
GAFa interaction Active site interaction
Figure 1.3 Domain Organizations of the Inhibitory Subunits of PDE6. The proline- 
rich region (P-rich) and polycationic region (PC region) at the N-terminal regon of Py 
subunits is responsible for the Py interaction with GAFa domain of PDE6. The a-helical 
region (a-helical), and the C-terminal (CT) residues are responsible for the Py binding to 
the active site of PDE6.
9
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A4. Pharmacology of PDE6
The substantial homology of PDE6 with PDE5 has implications for development 
of inhibitors targeting PDE5 or PDE6. Of the 11 mammalian PDE families, Rod and cone 
PDE6 is most closely related to PDE5 (abundant in vascular smooth muscle) in its 
biochemical, structural and pharmacological properties (Cote, 2004). Both PDE5 and 
PDE6 have highly conserved amino acid sequences (Figure 1.4) and 3-dimensional 
structures (Cote, 2004). PDE5 and PDE6 share strong substrate specificity for cGMP 
compared to cAMP (Beltman et al., 1995). Most PDE5-selective inhibitors, including 
sildenafil (Viagra; Pfizer) and vardenafil (Levitra; Bayer Pharmaceuticals)—two drugs 
approved for treatment of male erectile dysfunction—also potently target PDE6.
Indeed, a major challenge in developing PDE5-specific inhibitors for therapeutic 
purposes is the similarity in the catalytic sites of PDE5 and PDE6 with respect to drug 
binding. Preclinical and clinical data on the effects of sildenafil have revealed significant 
but transitory effects on visual function, presumably through inhibition of photoreceptor 
PDE6 (Laties and Zrenner, 2002). Sildenafil is a highly selective inhibitor of PDE5 (K; = 
4 nM) with one exception, namely its potent inhibition of rod and cone PDE6 (K; = 30 
nM) (Ballard et al., 1998; Zhang et al., 2005). Tadalafil and vardenafil, two other 
approved drugs, show lesser effects on visual function (Uckert et al., 2003). 
Electroretinogram studies have shown that PDE5 inhibitors exert a modest effect on 
visual function (Luu et al., 2001).
10
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Figure 1.4 Similar Domain Organizations between PDE5 and PDE6. The catalytic 
subunits of PDE5 and PDE6 share a similar domain organization. Both enzymes contain 
regulatory GAF domains which are responsible for noncatalytic cGMP binding. In 
addition, PDE6 GAFa also contains a region that interacts with the inhibitory y-subunit. 
The catalytic domains of PDE5 and PDE6 are also highly homologous, with a similar 
catalytic core containing metal ion binding sites. For PDE6, the Py binding site within the 
catalytic domain is responsible for the inhibition of hydrolysis upon Py binding. PDE6 
contains a famesyl (a subunit) or geranylgeranyl (13 subunit) group attached to its C- 
terminus while PDE5 has a phosphorylation site at its N-terminus.
Cyclic nucleotides (cAMP and cGMP) are second messengers in all eukaryotic 
cells. As the primary intracellular messenger for the light response in rod and cone 
photoreceptor cells, the cellular level of cGMP is precisely controlled by the balance of 
its synthesis (via guanylate cyclase) and its degradation (via PDE6). In the dark, cGMP is 
maintained at a high concentration that permits opening of some of the cGMP-gated ion 
channels. When exposed to light, the acceleration of PDE6 hydrolysis causes a rapid drop 
in cGMP levels leading to the closure of cGMP-gated ion channel and membrane 
hyperpolarization. It is obvious that the lifetime of activated PDE6 must be a highly
B. Visual Transduction
11
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regulated process. The activation of guanylate cyclase (regulated by calcium) to 
synthesize cGMP is coupled with PDE6 inactivation to quickly recover cGMP levels to 
their dark-adapted state.
B l. Rod and Cone Cells
The first step in seeing occurs in the retina where two classes of photoreceptor cells 
rods and cones (Figure 1.5), convert light into electrical signals which can be transmitted 
neurally to the brain. In darkness, the visual transduction pathway in rod photoreceptors 
has high photosensitivity and high amplification sufficient to detect even a single photon. 
But, during daylight illumination conditions, the rod photoresponse is saturated and 
vision depends on cone photoreceptors. Cone photoreceptors are much less sensitive than 
rods, but possess the important property that their photoresponses do not saturate even at 
the brightest illumination conditions. In addition, most vertebrates have only one visual 
pigment for rod and two or more types of cone photoreceptors that differ in the spectral 
sensitivity of their visual pigments. (Rodieck, 1998; Fain, 2003)
Although rod and cone photoreceptors share the same overall biochemical machinery 
to carry out phototransduction, they differ in many respects: (1) cellular anatomy; (2) the 
central phototransduction proteins (including rod and cone PDE6 subunits) in cones are 
homologous but not identical to those in rods; (3) a few photoreceptor proteins (e.g., 
GARP2) are only found in one photoreceptor type, or differentially expressed (e.g., RGS- 
9) in rods and cones. These differences are likely to account for some or all of the 
differences in rod and cone phototransduction pathways.
12






Figure 1.5 Schematic Diagram of Vertebrate Rod and Cone Photoreceptors. The
outer segment of a rod photoreceptor (left) consists of separate, flattened disk membranes 
which are stacked together. For cone cells (right), the outer segments are formed as 
continuous invaginations of the plasma membrane. Connected to the outer segment is the 
the mitochondria-rich ellipsoid portion of the inner segment which communicates with 
second-order retinal neurons.
The outer segment of rod and cone photoreceptors is the compartment where 
phototransduction occurs and where initial membrane hyperpolarization is triggered. The 
phototransducing outer segment portion of the cell consists of a densely packed 
membranous system optimized for photon capture and signal transduction. Thousands of 
separate, flattened disk membranes are stacked together in the rod outer segment, which 
are distinct from the plasma membrane. For cone cells, the outer segments are formed as 
continuous invaginations of the plasma membrane. The closely packed disk membranes 
in the outer segments greatly reduce free diffusion in the cytoplasm, resulting in the 
restricted spread of the visual excitation pathway. (Rodieck, 1998)
13
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B2. Visual Excitation Pathway
The disk membrane of the photoreceptor outer segment is the location 
where the protein components of visual excitation transform a photon of light into an 
amplified signaling pathway that leads to PDE6 activation and drop in cGMP levels. The 
drop in cellular cGMP causes closure of a plasma membrane channel that triggers a 
receptor potential. The central components of this disk membrane-localized signaling 
pathway consist of the integral membrane protein, rhodopsin, the heterotrimeric G- 
protein, transducin, and the photoreceptor PDE (PDE6). Rhodopsin is a 40 kDa, seven 
transmembrane segment receptor to which the chromophore 11-cis retinal is bound. The 
dense packing of rhodopsin molecules in the disk membrane (equivalent solution 
concentration of 6 mM) ensures a high probability of photon capture. Transducin is a 
peripheral membrane protein anchored to the disk membrane by both its myristoylated a- 
subunit and by its famesylated y-subunit (which exists in tight complex with its B- 
subunit). PDE6 is also confined to the disk membrane by isoprenylation of its catalytic 
subunits. The high concentrations of rhodopsin, transducin (0.6 mM), and PDE6 (20 pM) 
—along with their confinement to the disk membrane—serve to optimize the sensitivity, 
speed, and amplification properties of these initial events in vertebrate phototransduction.
The first step of seeing begins with the photoisomerization of 11-cis retinal to the 
all-trans isomer that is covalently bound to rhodopsin (Figure 1.6). Activated rhodopsin 
(R*) undergoes a conformational change in its cytoplasmic loops that allows this 
transmembrane receptor to bind and activate transducin. Transducin activation occurs 
when the Ta-GDP subunit (inactive) undergoes nucleotide exchange, and Ta-GTP 
(active) dissociates from the transducin (3y dimer. The released Ta-GTP then binds to the
14
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nonactivated PDE6 holoenzyme and displaces the inhibitory Py subunit to accelerate 
cGMP hydrolysis at the active site of PDE6. The rapid drop in cytoplasmic cGMP levels 
leads to dissociation of cGMP from the ligand-gated cation channel, and the channel 
changes from the open (dark) state to the closed (light) state. Membrane 
hyperpolarization results in generation of the receptor potential at the photoreceptor 
synapse.
As the main effector enzyme emphasizing visual signaling in photoreceptors, the 
activity of PDE6 has to be precisely regulated. A greater than 100-fold activation of 
PDE6 by transducin is coupled to catalytic rates for cGMP hydrolysis that approach the 
diffusion-controlled limit. In summary, PDE6 functions with high efficiency and in a 
highly controlled manner to regulate the cellular level of cGMP in the outer segment on 
the millisecond time scale required for vision (Pugh, Jr. and Lamb, 1993; Arshavsky et 
al., 2002).
15
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
i m r n m v T n n m f m f m m i T R i T r i f T m R m m v m m i
Ca2+/K+loo
Light-Activated
R*-T* Tot* P  Ta*-Prmiff il 0 2 5  Na+
5 5  Ca2+
T1
I I  Ca2+ 5-GMP
Figure 1.6 The Photo-excitation Pathway in Vertebrate Rod Photoreceptors. The
initial events of phototransduction occur on the physically separate disc membranes in the 
outer segment of rod cells. When light reaches the retina, photo-activation of rhodopsin 
(R*) catalyzes the activation of hundreds of heterotrimeric G-proteins, transducin (T). 
Then, T a-subunit (Ta) undergoes nucleotide exchange from GDP to GTP leaving 
transducin (3y-subunits. The associated Ta*-GTP subunit then interacts with the PDE6 
holoenzyme (P), displacing the y-subunit of PDE6 and relieving inhibition of catalysis at 
one catalytic subunit. The activation of PDE6 results in rapid hydrolysis of cytoplasmic 
cGMP. The drop in cGMP levels in the outer segment causes the closure of cGMP-gated 
ion channels and membrane hyperpolarization.
B3. Transducin Regulates PDE6
Upon transducin activation, the Py subunits of PDE6 are displaced from PaPyy by 
Ta-GTP, relieving the hydrolytic activity at the catalytic site of PDE6 (Stavenga et al., 
2000; Arshavsky et al., 2002). Whether each activated transducin Ta-GTP activates one 
or both PDE6 catalytic subunits is unclear at present. Some studies suggest that two 
activated transducins bind the PDE6 catalytic dimer (i.e., 1:1 subunit molar ratio) to
16
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stimulate hydrolytic activity to its full extent (Wensel and Stryer, 1990; Leskov et al., 
2000). Other reports suggest that single Ta-GTP was able to maximally activate the 
PDE6  catalytic dimer (i.e. 1:2 subunit molar ratio) under certain conditions (Bruckert et 
al., 1994; Melia et al., 2000; Yamazaki et al., 2002). The latter study suggested that either 
PDE6  catalytic dimer has only one functional active site, or that a single Ta-GTP can 
relieve Py inhibition at both active sites. Furthermore, it has been reported that activated 
transducin can activate PDE6  to about one-half of the rate that is seen if the y-subunits 
are physically removed from frog (Whalen et al., 1990; Norton et al., 2000) or bovine 
PDE6  (Melia et al., 2000; Gillespie, 1990). This has led to conflicting models of 
transducin activation of PDE6  in which transducin is hypothesized to relieve Py 
inhibition at either one or both catalytic sites of PDE6 .
Transducin activation also reduces Py affinity to the regulatory GAF domains of 
PDE6 , as judged by a 10-fold increase in the dissociation rate of cGMP from one GAF 
domain and a concomitant dissociation of one Py from the holoenzyme. The second 
GAFa domain of PDE6  retains high affinity for cGMP, and the second Py remains 
associated with the PDE6  catalytic dimer (Norton et al., 2000; Cote et al., 1994). The 
reciprocal positive cooperativity of cGMP and Py binding (mentioned in Section A2b) 
may be relevant to understanding the transducin activation mechanism. In particular, the 
heterogeneity and positive cooperativity of Py and cGMP binding to the two catalytic 
subunits of PDE6  suggest that activated Ta-GTP may interact differently with the two 
catalytic subunits as well. The consequences of PDE6  allosterism on the transducin 
activation mechanism are poorly understood, but may be critically important to a full
17
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understanding of the molecular mechanisms regulating the physiological response of 
photoreceptor cells to light.
C. Research Goals
Considering the fact that the visual transduction pathway is the best studied G- 
protein coupled signaling pathway, it is surprising that many questions about the function 
and regulation of PDE6  remain unanswered. For example, rod PDE6  exists as a Pafi 
catalytic dimer under all conditions that retain its enzymatic activity, but it is not clear 
whether one or both catalytic domains are active (Figure 1.7). Importantly, there is no 
consensus in the literature on the issue of whether transducin can relieve the inhibition of 
Py at one or both active sites of PDE6  (Figure 1.7). Another mystery is the role of the 
regulatory GAF domains of PDE6 . For two other GAF-containing PDEs (PDE2 and 
PDE5), cGMP binding to the GAF domains induces direct conformational changes within 
the catalytic subunits that relieves inhibition of catalysis at the active site of the enzyme 
(Martins et al., 1982; Yamamoto et al., 1983; Corbin et al., 2000; Okada and Asakawa, 
2002; Rybalkin et al., 2003). No direct allosteric communication between the GAF and 
catalytic domains of PDE6  has been reported to date (Arshavsky et al., 1992; Mou and 
Cote, 2001), although the close similarities of PDE5 and PDE6  suggest that PDE6  might 
also retain this direct allosteric mechanism.
In this thesis, I used the ability of PDE5 inhibitors to bind to the PDE6  active site 
to probe the properties of the catalytic mechanism of PDE6 . Using radiolabeled 
[3H] sildenafil and [3H]vardenafil provides a unique opportunity to test the accessibility of 
the catalytic sites of PDE6  catalytic dimer by the direct binding of inhibitor to the active
18
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sites. By determining the maximum stoichiometry of inhibitor binding to PDE6 , I will 
address the unanswered question of whether one or both catalytic sites are functional. 
Once this is determined, radiolabeled inhibitors will also be used to explore the 
mechanism of transducin activation of PDE6 , specifically whether transducin can release 
Py inhibition at one or both active sites. A third goal of my work is to examine the direct 
allosteric communication between the regulatory GAF domains and catalytic domains of 
PDE6  by examining changes in cGMP binding (to GAF domains) or inhibitor binding (to 
catalytic domains) when ligand occupies the other binding site. Finally, I will examine 
potential differences in the active sites of rod and cone PDE6  by testing a set of inhibitor 
compounds for their potency and relative selectivity for the purified rod PDE6  versus 
cone PDE6 .
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Figure 1.7 Regulation of PDE6 catalytic activity. The prevailing model of rod 
phototransduction asserts that the PDE6  catalytic dimer contains two active sites, both of 
which catalyze cGMP hydrolysis (part a, figure to right), and both of which are relieved 
of Py inhibition by the binding of two transducin aj* molecules (part b, figure to right). 
However, an alternative model has been proposed in which PDE6  has only one functional 
active site (part a, figure to left). Furthermore, it has been reported that transducin is only 
capable of activating PDE6  on ROS membranes to about 50% of the full catalytic rate of 
the PaB catalytic dimer, which suggests that transducin is only capable of activating one 
catalytic site on PDE6  (part b, figure to left). The work in this thesis seeks to resolve 
these unanswered questions.
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CHAPTER 2
PROBING THE CATALYTIC SITES AND ACTIVATION MECHANISM OF 
PHOTORECEPTOR PHOSPHODIESTERASE (PDE6) USING RADIOLABELED
PDE INHIBITORS
Abstract
Retinal photoreceptor phosphodiesterase (PDE6 ) is unique among the eleven 
vertebrate phosphodiesterase families not only for its catalytic heterodimer, but also for 
its regulatory y subunits (Py) whose inhibitory action is released upon binding to the G- 
protein, transducin. It has been assumed—but never demonstrated—that during visual 
excitation both PDE6  catalytic sites are relieved of Py inhibition by the binding of two 
activated transducin molecules. Since PDE6  shares significant structural and 
pharmacological similarities with PDE5, we utilized radiolabeled PDE inhibitors lacking 
selectivity for PDE5 versus PDE6  to probe the catalytic sites of rod PDE6 . The 
membrane filtration assay we used to quantify [ H]vardenafil binding to PDE6  required 
histone II-AS to stabilize drug binding to PDE6 . Under these conditions, [ H]vardenafil 
binds stoichiometrically to both the a and 6  catalytic subunits of the activated PDE6  
heterodimer. [3H]vardenafil is unable to bind to the PDE6  holoenzyme (a(3yy) consistent 
with Py blocking access to the drug binding sites. Following transducin activation of 
PDE6  holoenzyme on rod outer segment membranes, [ H]vardenafil binding increases
21
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proportionally as PDE6  is progressively activated by transducin. However, both 
[ H]vardenafil binding and hydrolytic activity of transducin-activated PDE6  approach 
only one-half of the value for PDE6  catalytic dimer lacking bound Py subunits. Addition 
of a 1 0 0 0 -fold excess of purified, activated transducin a-subunits reveals a second, low 
affinity binding site that can stimulate the hydrolytic activity of PDE6  to its maximum 
extent. These results demonstrate that each catalytic domain in the rod PDE6  heterodimer 
stoichiometrically binds radiolabeled inhibitor, and possesses full catalytic activity. 
Furthermore, activated transducin a-subunit has high and low affinity binding sites such 
that endogenous activated transducin activates only one-half of the maximum catalytic 
activity of the PDE6  catalytic dimer during visual excitation.
Introduction
The superfamily of phosphodiesterase (PDE) enzymes plays a critical role in 
maintaining the cellular levels of cyclic adenosine monophosphate (cAMP) and cyclic 
guanosine monophosphate (cGMP) (Beavo et al., 2006). Photoreceptor 
phosphodiesterase (PDE6 ) is the central effector responsible for lowering cGMP levels in 
photoreceptor cells following light stimulation. The PDE6  activation mechanism, its 
catalytic efficiency, and its substrate specificity are all designed to optimize the ability of 
photoreceptors to rapidly respond to light stimuli with subsecond changes in cGMP levels 
(Cote, 2006). During the first steps in vision, photoisomerized rhodopsin activates 
transducin, which binds GTP and releases its a-subunit (Ta-GTP) to activate membrane- 
associated rod PDE holoenzyme by displacing Py from the active sites of Pap. The drop 
in cGMP that results from PDE6  activation causes cGMP-gated ion channels to close,
22
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resulting in membrane hyperpolarization that is transmitted to second-order retinal 
neurons (Stavenga et al., 2000; Arshavsky et al., 2002).
Considering the wealth of quantitative information about the phototransduction 
pathway, it is surprising that important aspects of PDE6  function and regulation remain 
unknown. For example, rod PDE6  usually exists as a tightly associated catalytic dimer of 
a- and B-subunits (Pafl), but there are still questions about whether one or both of the 
catalytic domains are active. Underscoring this point is the fact that chicken rod 
photoreceptor PDE6  apparently contains only one functional catalytic subunit [B-subunit, 
(Huang et al., 2004)], raising the possibility that the catalytic site on the a-subunit in 
other species is not functional. More importantly, there is no consensus in the literature 
on the issue of whether transducin can fully activate PDE6  catalysis. Although it has been 
assumed that transducin can activate PDE6  in a 1:1 molar ratio (Wensel and Stryer, 1990; 
Leskov et al., 2000), the question of whether one or both PDE6  catalytic sites become 
activated by transducin during visual excitation has never been demonstrated. In some 
instances, it has been reported that two Ta-GTP bind to both catalytic subunits of PaB 
releasing the Py inhibition at both active sites (Pugh and Lamb, 2000; Wensel and Stryer, 
1990). Other investigators have reported that a single Ta-GTP was able to maximally 
activate the PDE6  catalytic dimer under defined conditions (Bruckert et al., 1994; Melia 
et al., 2000; Yamazaki et al., 2002). The latter work suggests that either the PDE6  
catalytic dimer has only one functional active site, or that a single activated Ta-GTP can 
relieve Py inhibition at both PaP active sites. Furthermore, it is reported that transducin 
can activate PDE6  to about one-half of the rate that is seen if the y-subunits are physically 
removed from PDE6  in frog (Whalen et al., 1990; Norton et al., 2000) and bovine (Melia
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et al., 2000; Gillespie, 1990) rod outer segments. This has led to conflicting models of 
transducin activation of PDE6  in which transducin is hypothesized to relieve Py 
inhibition at either one or both catalytic sites of PDE6 .
PDE6  differs in several fundamental ways from the other ten classes of 
mammalian phosphodiesterases. Rod PDE6  is the only PDE that exists as a catalytic 
heterodimer (PaB), whereas cone PDE6  and the other ten PDE families are all believed to 
be homodimers. Unlike other PDE families, rod and cone PDE6  catalytic activity is 
primarily regulated by its inhibitory Py subunits tightly associated with PaB to form an 
inactive tetrameric holoenzyme (a(3yy). PDE6  is also the only family of PDEs in which 
the catalytic activity is directly regulated by a heterotrimeric G-protein, transducin (Cote, 
2006).
PDE6  is most closed related to PDE5 (abundant in vascular smooth muscle) in its 
biochemical, structural and pharmacological properties (Cote, 2004). Both PDE5 and 
PDE6  have highly conserved amino acid sequences and 3-dimentional structures 
(McAllister-Lucas et al., 1993; Kameni Tcheudji et al., 2001). PDE5 and PDE6  share 
strong substrate specificity for cGMP compared to cAMP (Beltman et al., 1995). Both 
can bind cGMP with high affinity at their regulatory GAF domains (Francis et al., 2006; 
Cote, 2006). Most PDE5-selective inhibitors, including the well-known erectile 
dysfunction drugs Viagra (sildenafil) and Levitra (vardenafil), can also potently inhibit 
PDE6  catalysis as well (Gillespie and Beavo, 1989b; D'Amours et al., 1999; Zhang et al., 
2005).
We used the ability of PDE5 inhibitors to bind with high affinity to PDE6  to 
probe the active sites of the enzyme and to better elucidate the activation mechanism by
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transducin. Using [ H]vardenafil, we tested the hypothesis that both catalytic domains of 
the PaB dimer are catalytically active and functionally equivalent. We then evaluated 
whether binding of activated transducin to the PDE6  holoenzyme relieves inhibition at 
one or both of the active sites in the PDE6  dimer.
Experimental Procedures
Materials—Bovine retinas were purchased from W.L. Lawson, Inc.. Superdex 
200 and Mono-Q columns were from GE Healthcare, Inc., and the C l8 reversed-phase 
column (300A, 22x250 mm) was from Vydac. Filtration and ultrafiltration products were 
from Millipore. Scintillation fluid (Ultima Gold-XR) and [3H]cGMP was from 
PerkinElmer Life Sciences and [3H]vardenafil was a kind gift of Drs. P. Sandner & U. 
Pleiss (Bayer Healthcare AG). Protein assay reagents were from Pierce and all other 
chemicals were obtained from Sigma.
Preparation o f bovine rod outer segments (ROS), PDE holoenzyme and PDE 
heterodimer—Bovine rod outer segments (ROS) were prepared from frozen bovine 
retinas under dark-adapted conditions on a discontinuous sucrose gradient (Pentia et al., 
2005). PDE6  holoenzyme (PaPyy) was extracted with a hypotonic buffer from 
illuminated ROS homogenates and purified by Mono-Q anion-exchange chromatography 
and Superdex 200 gel filtration chromatography. The purified PDE6  (> 95% pure) was 
then concentrated by ultrafiltration and stored with 50% glycerol at -20°C (Pentia et al., 
2005).
The PDE6  catalytic dimer (PaB) was prepared from the PDE6  holoenzyme by 
removing the inhibitory Py subunits through limited trypsin proteolysis (Hurley and
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Stryer, 1982). A time course of proteolytic activation of PDE6  was determined to ensure 
that >90% of the Py subunit was destroyed without altering the apparent molecular 
weight of the catalytic subunits [as judged by SDS-PAGE; (Pentia et al., 2005)].
The concentration of PDE6  was determined by both measurements of catalytic 
activity under conditions were the kcat was known [5600 s'1; (Mou and Cote, 2001)] and 
by measurements of [ H]cGMP binding under conditions where maximum binding 
occupancy was achieved [(Bmax = 2.0 cGMP per PDE6 ; (Cote, 2000)].
Purification o f persistently activated transducin a-subunit (Ta-GTPyS)— 
Transducin a-subunits were extracted from the PDE6 -depleted ROS membranes by 
adding 50 pM GTPyS (in low salt buffer) to the ROS membranes and recovering the 
solubilized Ta-GTPyS by centrifugation. The extracted Ta-GTPyS was purified on a Blue 
Sepharose column (Kleuss et al., 1987; Wensel et al., 2005). The concentration of Ta- 
GTPyS was determined by a colorimetric protein assay. Purified Ta-GTPyS was stored 
with 50 pM GTPyS and 50% glycerol at -20°C.
Preparation and purification o f Py and Py63-87—Wild-type bovine rod Py (87 
amino acids) and the N-terminal truncated Py mutant, Pyl-45C (Skiba et al., 1996) were 
expressed in E. coli and purified to >97% purity using SP-Sepharose followed by 
reversed-phase high pressure liquid chromatography (Granovsky et al., 2000). The wild- 
type Py concentration was determined spectrophotometrically using an experimentally 
determined extinction coefficient of 7550 cm' 1 M' 1 (Cote, 2000). The inhibitory activity 
of purified Py was assayed by its ability to stoichiometrically inhibit trypsin-activated 
bovine rod PDE (Mou et al., 1999). The spectrophotometric and activity estimates of Py 
concentration agree to within 10% for all wild-type Py preparations used in this study.
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The concentration of the synthetic peptide Py63-87 (New England Peptide, Inc.) was 
determined by a protein assay.
Transducin activation o f ROS PDE—Purified ROS were resuspended in buffer A 
(20 mM MOPS, 2 mM MgCE, 30 mM KC1, 120 mM NaCl, pH 7.4) at a concentration of 
30 pM rhodopsin, and then passed through a 26 gauge insulin needle ten times under dim 
red light. The concentration of membrane-associated PDE was estimated based on its 
stoichiometric ratio to rhodopsin (300 rhodopsin per PDE6 ) and its maximum hydrolytic 
activity after trypsin proteolysis. After ROS homogenates were fully bleached by light to 
activate rhodopsin, PDE6  was activated by incubating with an excess of GTPyS relative 
to the transducin concentration and the rate of cGMP hydrolysis assayed.
Binding o f [  HJvardenafil to catalytic sites on PDE—The membrane filtration 
assay to quantitate [ H]vardenafil binding to PDE6  was adapted from a similar assay for 
PDE5 (Blount et al., 2004). The standard binding assay buffer contained histone Type II- 
AS (0.2 mg/ml). To reduce nonspecific binding, samples were diluted 20-fold with ice- 
cold wash buffer (10 mM Tris, pH 7.5, 0.1% Triton X-100) immediately before applying 
the sample onto pre-wet Millipore HAWP 025 membrane filters. Filters were washed 8 
times with 1 -ml ice-cold wash buffer.
Analytical methods: The rate of cGMP hydrolysis was determined by a phosphate 
release assay (Cote, 2000). Activity measurements were made in 100 mM Tris (pH 7.5) 
buffer containing: 10 mM MgCl2, 0.5 mg/ml BSA, 0.5 mM EDTA, 2 mM dithiothreitol. 
All rate measurements were obtained from four individual time points at saturating 
cGMP concentrations (10 mM) and less than 30% substrate was consumed during this 
time. The [ H]cGMP membrane filtration binding assay was used to determine the
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stoichiometry of cGMP binding under various conditions (Cote, 2005) with 10 mM 
EDTA and 50 pM vardenafil added to the binding assay solution to prevent cGMP 
hydrolysis. The rhodopsin concentration was spectrophotometrically determined, using 
an extinction coefficient of 42000 M^cm"1 (Bownds et al., 1971).
Results and Discusion
Histone II-AS stabilizes [3HJvardenafil binding to the catalytic sites o f  PDE6 
catalytic dimer—Previous work has shown that most of the so-called PDE5-selective 
inhibitors (e.g., zaprinast, E4021, sildenafil, and vardenafil) also inhibit the catalytic 
activity of the closely related photoreceptor PDE6  (Gillespie and Beavo, 1989b; 
D'Amours et al., 1999; Zhang et al., 2005). To date, vardenafil is the most potent of this 
class of catalytic site inhibitor, with an inhibition constant for PDE6  of ~ 1 nM (Zhang et 
al., 2005). As such, it represents a useful tool for probing the active sites of PDE6  in its 
nonactivated and activated states. Initial experiments measuring [3H]vardenafil binding to 
purified PDE6  using a membrane filtration assay revealed high nonspecific binding and 
variability in total binding. There was no detected binding of vardenafil to PaB alone. 
Consistent with previous studies of PDE5 binding to radiolabeled inhibitors (Blount et 
al., 2004), we observed that histone II-AS stabilized [3H]vardenafil binding to PDE6  
catalytic dimer (PaB) in a concentration-dependent manner (Figure 2.1). Interestingly, 
histone II-AS had minor effects on cGMP hydrolytic activity at the active site or the 
ability of [3H]cGMP to bind to the regulatory GAF domains (data not shown). The 
mechanism of histone II-AS effects on PDE5 or PDE6  is still not clear, but one likely
28
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possibility is that histone II-AS slows down drug dissociation during the washing step of 
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Figure 2.1 Histone II-AS Stimulates Binding of [3H]vardenafil to the Active Sites of 
PDE6 Catalytic Dimer. Purified PaP catalytic dimer ( 6  nM) lacking Py was incubated 
with 70 nM [3H]vardenafil and increasing amounts of histone II-AS at room temperature 
for 40 min. The amount of radiolabeled drug was determined by a membrane filtration 
assay (see Experimental Procedures). Data represent one of three similar experiments.
To further characterize the unexpected stabilization of [3H]vardenafil binding by 
histone II-AS, we tested several other known PDE6 -interacting compounds, including 
histone Type VIII-S (Miki et al., 1975; Hurwitz et al., 1984), Py, and Py peptides. Histone 
VIII-S, which historically has been used to displace Py and activate the PDE6  
holoenzyme, can stabilize vardenafil binding to the PaB dimer to a certain extent (Figure 
2.2), but did not reach the maximum binding observed with histone II-AS. Little 
[3H]vardenafil binding was detected with Py or the C-terminal peptide Py63-87, as might
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be expected since the C-terminal region of the inhibitory Py subunits competes with drug 
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Figure 2.2 Comparison of [3H]vardenafil Binding to Pali Stimulated by Histones or
Py. Purified PaB (5 nM) and 70 nM [3H]vardenafil were incubated with the following for 
40 min at room temperature: 10 mM Tris (pH 7.5), 0.2 mg/ml histone II-AS, 0.2 mg/ml 
histone VIII-S, 10 pM Py or 10 pM Py63-87. Vardenafil binding was quantified by the 
membrane filtration assay.
f  HJvardenafil binds to PDE6 catalytic dimer, but Py blocks inhibitor binding to 
the holoenzyme—It is well established that rod PDE6  consists of a and B catalytic 
subunits, and it has been assumed, but never demonstrated, that each catalytic domain of 
PaB is active. The binding assay for [3H]vardenafil allowed us to directly test this by 
comparing catalytic activity, cGMP binding stoichiometry and [ H] vardenafil binding in 
the same PaB catalytic dimer preparation.
Figure 2.3 shows that the binding curve for [3H]vardenafil to purified PaB 
displays a single class of drug binding sites. The apparent binding affinity for vardenafil 
is high, but lower than the reported value of the inhibition constant [K; = 0.7 nM, (Zhang
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et al., 2005)]. This discrepancy is due to the requirement for nanomolar levels of PDE6  to 
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Figure 2.3 [3H]vardenafil Binds Stoichiometrically to Each PaB Catalytic Subunit, 
But Only in the Absence of Py. Purified PaB (2.5 nM; filled circles) or PaB 
reconstituted with Py (10 pM; open circles) was incubated with 0.2 mg/ml histone II-AS 
and the indicated concentration of [3H]vardenafil. Samples were incubated for 40 min 
before membrane filtration. Vardenafil binding was normalized to the PaB concentration, 
as estimated by both [ H]cGMP binding assay, as well as hydrolytic activity 
measurements (which agreed to within 10%). [3H]vardenafil binding to PaB was fit 
assuming a single class of binding sites (Kd = 7.8 nM and Bmax = 2.0). The data is 
representative of 3 similar experiments.
site as the vardenafil concentration is increased [This interpretation is supported by 
experiments in which the apparent Kq for [ HJvardenafil binding decreased as the PDE6  
concentration was lowered (data not shown)]. The maximum extent of vardenafil binding 
to purified PaB was calculated to be 2.0 vardenafil molecules per PaB. This result shows 
that both the a and 6  catalytic subunits of PDE6  bind vardenafil equally well. In contrast, 
the same Pa(3 reconstituted with Py cannot bind [ HJvardenafil to a significant extent
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under identical experimental conditions (Figure 2.3), demonstrating that vardenafil 
binding is prevented when Py inhibits the catalytic site of PDE6 .
Endogenous activated transducin relieves Py inhibition o f only one-half o f the fu ll 
catalytic potential o f PDE6 on ROS membranes—To evaluate the extent to which 
transducin can stimulate PDE6  catalysis and permit binding of [ H]vardenafil to the 
PDE6  catalytic sites, we used ROS homogenates in which the key proteins of visual 
excitation (rhodopsin, transducin, and PDE6 ) remain associated with the disk membrane. 
The use of ROS homogenates was necessitated by the well-established fact that 
transducin poorly activates rod PDE6  when both proteins are not bound to ROS disk 
membranes (Wensel and Stryer, 1988; Gillespie and Beavo, 1988). The analysis of these 
experiments was simplified because PDE6  is the only enzyme present in ROS 
homogenates capable of breaking down cGMP and of binding vardenafil.
We found that when transducin is inactive (i.e., in the absence of GTPyS), PDE6  
hydrolytic activity in these ROS homogenate preparations was low (<10% of the fully 
activated rate) as was the ability of PDE6  to bind [3H]vardenafil (Figure 2.4). In addition, 
limited trypsin proteolysis of ROS homogenates (to fully degrade the Py subunits and 
activate PDE6  catalysis) resulted in stoichiometric binding of [ HJvardenafil (1.9 + 0.2 
mol vardenafil per mol PDE6  catalytic dimer) and complete activation of cGMP 
hydrolysis (Figure 2.4). Surprisingly, transducin activation of PDE6  failed to activate 
more than 38 + 5% of the full catalytic potential of the enzyme. The maximum extent of 
PDE6  catalytic stimulation was consistent with this observation in that only 0.9 ± 0.1 mol 
vardenafil per mol PDE6—not 2 mol per mol—was able to access the catalytic sites of 
transducin-activated PDE6 .
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Figure 2.4 Transducin-activated PDE6 Achieves Only One-half of the Extent of 
[3H]vardenafil Binding or Hydrolytic Activity Compared to PaB. Light-exposed ROS 
homogenates were prepared (see Experimental Procedures) and portions were incubated 
with either buffer (nonactivated) or with 50 pM GTPyS (to activate transducin). A 
separate portion was exposed to trypsin to maximally activate PDE6  catalysis. The 
samples (containing 4 nM PDE6 ) were incubated with 74 nM [3H]vardenafil for 40 min 
before membrane filtration (black bars) and activity assays (gray bars). Data are the mean 
± S.D. of three experiments.
To further explore this relationship between stimulation of PDE6  catalysis by 
transducin and the availability of the PDE6  active site to bind radiolabeled drug, we 
added increasing amounts of GTPyS to light-exposed ROS homogenates to progressively 
activate transducin (and hence PDE6 ). Figure 2.5 shows an excellent correlation between 
stimulation of catalysis and [ H]vardenafil binding as the fraction of activated transducin 
was increased. These results also confirmed that a maximum of approximately one-half 
of the catalytic sites on PDE6  are dis-inhibited upon transducin activation, as judged by
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both accessibility of vardenafil to the PDE6  active site as well as by the extent of 
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Figure 2.5 [3H]vardenafil Binding Correlates with the Extent of PDE6 Activation by 
Transducin. Increasing concentrations of GTPyS were added to ROS homogenates (10 
nM PDE6 ) to progressively activate PDE6 . The extent of PDE6  activation was quantified 
by measuring cGMP hydrolytic rates (filled circles) and normalized to the activity of the 
same sample activated by limited trypsin proteolysis. In separate samples, the amount of 
[3H]vardenafil bound was determined (open circles). A correlation plot (inset) shows a 
linear relationship of activation and vardenafil binding (r2=0.96).
Because this result differs from the commonly held view that transducin can fully 
activate PDE6  during visual excitation, we next explored whether addition of exogenous, 
activated transducin (i.e., greater than the endogenous levels present in the ROS 
homogenates) could further stimulate PDE6  catalysis. We purified the a-subunit of 
transducin bound to GTPyS (Ta-GTPyS) and added increasing concentrations to either 
ROS homogenates or to purified, soluble PDE6  holoenzyme. As seen in Figure 2.6, 
addition of increasing concentrations of purified Ta-GTPyS to ROS homogenates (open
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circles) elevated PDE6  catalytic activity from 35 ± 4% to 101 ± 1% of the activity of 
catalytic dimers in which Py had been proteolytically removed. This demonstrates that a 
second activated Ta can bind to a second Py subunit and displace it from its active site, 
but does so with a relatively low binding affinity (i.e., requiring a greater than 1 0 0 0 -fold 
excess of exogenous activated Ta). Similar results were seen for purified, soluble PDE6  
in the absence of ROS disk membranes (Figure 2.6), but in this instance an even greater 
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Figure 2.6 A Large Excess of Activated Transducin a-subunit Fully Relieves Py 
Inhibition of Both Active Sites of the PDE6 Catalytic Dimer. The indicated 
concentrations of purified transducin a-subunits with GTPyS bound (Ta-GTPyS) was 
added to either 1 nM purified PDE6  holoenzyme (filled circles) or 2 nM ROS-PDE6  
previously incubated with 50 pM GTPyS to activate endogenous transducin (open 
circles). In both cases, hydrolytic rates were normalized by comparison to the catalytic 
activity of samples that had been treated with trypsin to fully activate PDE6  catalysis. 
Data are the mean ± S.D. of two experiments.
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Conclusions
Two major conclusions emerge from this work. The first is that each catalytic 
subunit of the rod heterodimer possesses full catalytic activity (Figure 2.7, left-most 
diagram). This conclusion was demonstrated by the innovative approach of utilizing 
radiolabeled vardenafil to quantify the number of binding sites with respect to the 
catalytic activity and cGMP binding stoichiometry of identical PaB preparations. The 
second major conclusion is that activated transducin only activates one-half of the active 
sites of PDE6  with high efficiency, and that a second low affinity transducin binding site 
on PDE6  is observed only when a large excess of exogenous transducin is present.
The photoreceptor outer segment provides a unique cellular enviroment for visual 
transduction and specifically for regulation of PDE6  activation by transducin. The high 
concentration of transducin [about 500 pM; (Pugh and Lamb, 2000)] relative to PDE6  
(20pM) ensures the efficiency of propagation of the excitation pathway (Arshavsky et al., 
2002). However, the high affinity of the Py subunits for PaB not only prevent “dark” 
activation of PDE6  under dark-adapted conditions [the basal activity of rod PDE6  is 
equivalent to only 1 out of 2200 PaB being fully active (Rieke and Baylor, 1996; 
D'Amours and Cote, 1999)], it also poses a challenge for transducin to displace Py during 
the activation mechanism. Our observation that transducin only activates PDE6  activity 
to its half-maximum potential suggests that only one Py site is dis-inhibited during visual 
excitation. The second Py site may only be dis-inhibited upon prolonged illumination, in 
which a sustained drop in the cGMP concentration within the outer segments may cause 
dissociation of cGMP from the PDE6  GAF domain. This in turn would decrease the Py 
affinity, thereby allowing the second catalytic site of PDE6  to be activated by transducin.
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Although we observed the complete activation of PDE6  only when exogenous Ta-GTPyS 
was added in vitro, in fact the transducin concentration in the outer segment of a living 
photoreceptor easily achieved the concentration needed to activate both catalytic sites of 
PDE6 . The idea that two distinct transducin sites on PDE6  are used for dark-adapted and 
light-adapted conditions provides a biochemical rationale for the ability of photoreceptors 
to modulate sensitivity over 2-3 orders of magnitude.
GMP GMP GMP GMP GMP
Figure 2.7 Mechanism of PDE6 Activation. In its nonactivated state, the catalytic 
activity of rod PDE6  holoenzyme is fully inhibited by two Py subunits (black s-shaped 
rods) binding to the PaB heterodimer (represented as having one catalytic domain and a 
tandem GAF regulatory domain per catalytic subunit). Physical removal of both Py 
subunits by limited proteolysis (Process A) allows full catalytic activity of each of the 
two active sites. Activation of ROS-membrane associated PDE6  by endogenous 
transducin results in activation of one-half of the full catalytic potential of PDE6 , most 
likely by binding to and displacing a lower affinity Py subunit from its interaction site on 
one catalytic subunit (Process B). Addition of a large excess of Ta-GTPyS reveals a 
second transducin interacting site that displaces the second Py subunit from its higher 
affinity interaction with the catalytic site, thereby leading to full catalytic activation 
(Process C).









Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
CHAPTER 3
BIOCHEMICAL APPROACHES TO STUDY THE CATALYTIC AND 
ALLOSTERIC PROPERTIES OF PHOTORECEPTOR PHOSPHODIESTERASE
(PDE6)
Introduction
PDE6  is the central enzyme in phototransduction in rod and cone photoreceptor 
cells. Rod PDE6  is a tetramer, consisting of two inhibitory y subunits tightly bound to a 
and 13 subunits (Baehr et al., 1979; Deterre et al., 1988). Cone PDE6  contains two 
identical a ’ subunits, to which cone-specific y’ subunits bind with unknown 
stoichiometry. The cone y’ subunit is slightly smaller than rod y (Hamilton and Hurley, 
1990) and the affinity of cone y’ subunits binding to PDE6  is weaker than rod y subunits 
(Hamilton et al., 1993; Valeriani, 2004). Although the physical responses of rod and cone 
to light differ, rod and cone PDE6  have similar kinetic properties [i.e. similar Km and kcat 
values (Gillespie and Beavo, 1988; Huang et al., 2004; Mou and Cote, 2001)].
PDE6 Pharmacology
The rod and cone photoreceptor PDE6  belongs to a superfamily of 11 distinct 
cyclic nucleotide PDEs (Beavo et al., 2006). Not only are rod and cone PDE6  most
38
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
closely related to PDE5 (abundant in vascular smooth muscle) in their biochemical and 
structural properties (Cote, 2004), most drugs that selectively and potently target PDE5 
also inhibit PDE6  as well. Preclinical and clinical data on the effects of sildenafil have 
revealed significant but transitory effects on visual function, presumably through 
inhibition of photoreceptor PDE6  (Laties and Zrenner, 2002). Tadalafil and vardenafil, 
two other approved drugs, show smaller effects on visual function (Uckert et al., 2003). 
Remarkably little is known about the effects of PDE5-selective drugs on cGMP 
metabolism in photoreceptors (Zhang et al., 2005). Of the few reports comparing the 
pharmacology of purified rod and cone PDE6  to date, few compounds have been show to 
discriminate these two isoforms. In this study, we surveyed the potency and selectivity of 
a series of PDE inhibitors originally designed to target PDE5, in the hope of identifying 
compounds that discriminate purified rod and cone PDE6 , and thereby provide insights 
into differences in the catalytic sites of the two isoforms.
Function of Regulatory GAF Domains of PDE6
Five members of the cyclic nucleotide phosphodiesterase (PDE) superfamily 
contain N-terminal regulatory domains that consist of a tandem pair of GAF domains. For 
PDE2 and PDE5, cGMP binding to the N-terminal regulatory GAF domains induce 
conformational changes that relieve inhibition of catalysis in the C-terminal active sites 
of the enzyme (Martins et al., 1982; Yamamoto et al., 1983; Corbin et al., 2000; Okada 
and Asakawa, 2002; Rybalkin et al., 2003). For PDE6 , its regulatory GAF domains 
contain both cGMP binding sites and Py binding sites. Occupancy of the PDE6  GAF 
domains by cGMP enhances Py affinity for its catalytic subunits (Yamazaki et al., 1990;
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Cote et al., 1994; D'Amours and Cote, 1999). No direct allosteric communication 
between the GAF and catalytic domains of PDE6  has been reported to date (Arshavsky et 
al., 1992; Mou and Cote, 2001). In this chapter, we report that occupancy of the GAF 
domains by an N-terminal Py peptide stabilizes binding of PDE inhibitor to the catalytic 
sites. Other regions of Py (or full length Py) fail to stabilize inhibitor binding. Unlike 
zaprinast and IBMX, the binding of two PDE5/6-selective inhibitors (sildenafil and 
vardenafil) to PDE6  catalytic sites lead to the shift of the low affinity cGMP binding site 
to a higher affinity site when Py is absent. This provides evidence for direct allosteric 
communication between regulatory and catalytic domains of the PDE6  catalytic dimer.
Experimental Procedures
Materials—Bovine retinas were purchased from W.L. Lawson, Inc.. Superdex 
200 and Mono-Q columns were from GE Healthcare, and the C l8  reversed-phase column 
(300 angstroms, 22x250 mm) was from Vydac. Filtration and ultrafiltration products 
were from Millipore, except for glass fiber filters (catalog #66085, Gelman, or #32, 
Schleichter and Schull). Scintillation fluid (Ultima Gold-XR) and [3H]cGMP were 
purchased from PerkinElmer Life Sciences . [3H]vardenafil was a kind gift of Drs. P. 
Sandner & U. Pleiss (Bayer Healthcare AG). [3H]sildenafil was a kind gift of Drs. Jackie 
Corbin and Sharron Francis (Vanderbilt University School of Medicine). Other PDE 
inhibitor compounds were a kind gift of Dr. Vince Florio (ICOS Corp.). Protein assay 
reagents were from Pierce and all other chemicals were obtained from Sigma.
Preparation o f bovine rod outer segments (ROS), rod PDE6 holoenzyme 
(PDE6R) or rod PDE6 heterodimer (Pafi)—PDE6 R and Pa6  were purified from ROS,
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which was prepared from bovine retina under dark-adapted conditions; as described in 
chapter 2 (Pentia et al., 2005).
Preparation o f bovine cone PDE6 (PDE6C) and cone catalytic dimer (Pa ’2)— 
The soluble PDE6 C was extracted from commercial frozen bovine retinas under dark- 
adapted conditions and purified with Q-Sepharose resin using a Pharmacia XK26 column 
(Pentia et al., 2005). The partially purified PDE6 C was stored in 50% glycerol at -20 °C. 
Pa ’2 was prepared by limited proteolysis, as described in chapter 2 for rod PaB. The 
concentration of PDE6 C was determined by measurements of catalytic activity under 
conditions where the kcat was known [4200 cGMP per Pa ’2 per second; (Valeriani, 
2004)].
Assay o f inhibition o f PDE6 hydrolysis by inhibitor compounds— PDE inhibitors 
were prepared in DMSO (100 mM stock concentration) due to their poor solubility in 
water. PaB or Pa ’2 (2 pM final concentration) purified from the same initial retinal 
homogenates (see above) were pre-incubated with inhibitors before addition of 1 pM 
[3H]cGMP. The hydrolytic reaction was then stopped by addition of HC1 at four different 
time points (1, 3, 5, 7 min). Control samples, either lacking PDE6  (negative control) or 
permitted to fully degrade the [ HJcGMP for 40 min (positive control), were included in 
all experiments. Following treatment of each sample with 5’-nucleotidase to degrade 5’-
•5
GMP to guanosine, the [ Hjguanosine was quantified by chromatography using DEAE- 
Sephadex A-25 resin (Cote, 2000).
Preparation and purification o f Py and Pyl-45— Full length bovine rod Py (87 
amino acids) was expressed in E. coli, purified and tested as described (Granovsky et al.,
2000). The truncated Py mutant, Pyl-45C (Skiba et al., 1996) was expressed in E. coli
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and purified to >97% purity using SP-Sepharose followed by reversed-phase high 
pressure liquid chromatography (Granovsky et al., 2000). The concentration of the 
synthetic peptide Py63-87 (New England Peptide) was determined by a protein 
colorimetric assay.
Transducin activation o f  ROS PDE6—Transducin-activated PDE6  was prepared 
exactly as described in Chapter 2.
Binding o f [  Hjvardenafil to catalytic sites on PDE6— The membrane filtration 
assay to quantitate [ H]vardenafil binding to PDE6  was adapted from a similar assay for 
PDE5 (Blount et al., 2004). The standard binding assay buffer contained histone II-AS 
(0.2 mg/ml). To routinely reduce nonspecific binding, samples were diluted 20-fold with 
ice-cold wash buffer (10 mM Tris, pH 7.5, 0.1% Triton X-100) immediately before 
applying the sample onto pre-wet membrane filters (Millipore, 0.45 pM HA). Filters 
were washed 8 times with 1 -ml ice-cold wash buffer, and radioactivity trapped on the 
filter quantified by scintillation counting.
3
Binding o f [  HJcGMP to GAF domain on PDE6—Purified PDE6  holoenzyme 
was carefully trypsinized to reach 90% of its maximum hydrolytic activity, followed by a 
3 hour incubation at 30°C to degrade endogenous cGMP present in the PDE6  sample. 
The cGMP-depleted, activated PDE6  was then treated with 10 mM EDTA to chelate
•3
divalent cations and prevent hydrolysis of [ H]cGMP during the binding assay. 5 nM 
EDTA-treated PDE6  and 1 pM [3H]cGMP were incubated in a 37°C water bath for 5 min 
before membrane filtration (Cote, 2005). Parallel measurements of the PDE6  
concentration were based on hydrolytic activity measurements.
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Analytical methods—Except where noted, the rate of cGMP hydrolysis was 
routinely determined by a phosphate release assay (Cote, 2000). Activity measurements 
were made in 100 mM Tris (pH 7.5) buffer containing 10 mM MgCl2, 0.5 mg/ml BSA, 
0.5 mM EDTA, and 2 mM dithiothreitol. All rate measurements were obtained from four 
individual time points at saturating cGMP concentrations (10 mM) and less than 30% 
substrate was consumed during this time. The rhodopsin concentration was 
spectrophotometrically determined by difference spectroscopy, using an extinction 
coefficient of 42,000 M '1cm~1 (Bownds et al., 1971).
The inhibition constant (Kj) was calculated from the sigmoidal concentration 
dependence curve using the equation: Kj = IC50/ (1+[S]/Km) (Cheng and Prusoff, 1973), 
where IC50 is the concentration of inhibitor that reduces catalytic activity in vitro by 50%, 
[S] is the substrate concentration, and Km is the Michaelis constant. According to this 
equation, if  the concentration of cGMP is much lower than Km, then Ki ~ IC50. The 
following values for Km were used: 14 pM for purified bovine rod PDE6  (Mou and Cote,
2001); 7 pM for purified bovine cone PDE6  (Valeriani, 2004). Unless noted, all 
experiments were repeated at least three times, and average values are reported. Curve 
fitting was performed using Sigmaplot.
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Results and Discussion
A . Inhibitor Binding to the Catalytic Site of Rod PDE6 versus Cone PDE6
Previous studies of the enzymological properties of PDE6  indicated that rod and 
cone PDE6  share similar kinetic properties (Gillespie and Beavo, 1988; Huang et al., 
2004; Mou and Cote, 2001; Valeriani, 2004). PDE6  inhibitors, which potently inhibit rod 
PDE6  (PDE6 R) can strongly target cone PDE6  (PDE6 C) as well. We tested a novel set of 
PDE5 inhibitors developed by ICOS for their ability to inhibit purified PDE6  in the hope 
that structural difference in the drug binding sites might be uncovered. Both PDE6 R and 
PDE6 C were tested in their fully activated state in which the inhibition by Py subunits 
were physically removed by limited proteolysis. Dose-response curves were generated 
for each inhibitor (a representative example is presented in Figure 3.1), and the drug 
inhibition constant (Ki) was calculated (see Methods) based on the IC50 obtained by 
curve-fitting analysis. The results of testing ten such inhibitors are summarized in Table 
1. 1.
The results showed that B4 and Ci were the most potent in inhibiting rod and cone 
PDE6 , while A3 and B3 were less potent inhibitors of all the compounds tested. The 
potency of all ten inhibitors tested was much lower than the well-known PDE5/6 
inhibitor, vardenafil (Kj < 1 nM). When examining pharmacological differences between 
rod and cone PDE6 , none of the compounds tested showed a strong preference for 
inhibiting rod or cone PDE6  isozymes. Inhibitors A3, B3, and B4 showed about 2-fold 
preference for inhibiting PDE6 C compared to the PDE6 R, whereas inhibitor Bi showed a 
3-fold preference for binding to PDE6 R compared to PDE6 C. These minor differences
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may be due to subtle differences in amino acid residues contacting these inhibitors within 













Figure 3.1 Dose-response Curves for Inhibition of PDE6R and PDE6C by 
Compound Ci. Purified PDE6R and PDE6C were activated by destroying the Py 
subunits (see Methods) and then 2 pM concentration of PDE6R (filled circles) or PDE6C 
(open circles) were incubated with PDE inhibitor “Ci” at the indicated concentration for 
15 min. 1 pM [ HJcGMP was then added to assay catalytic activity using a radiotracer 
assay (see Methods). The data points for each enzyme were fit to a 3-parameter sigmoidal 
function using Sigmaplot. The Ki values for this individual experiment (typical of 3 other 
experiments) were: PDE6R, IC50 =155 nM, PDE6C, IC50 = 213 nM.
PDE6 varies greatly in its ability to be inhibited by various classes of inhibitor 
compounds (Zhang et al., 2005). These may reflect the unique catalytic properties of the 
photoreceptor enzyme. PDE6 operates with very high catalytic efficiency for cGMP. 
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constant (up to 8000 cGMP hydrolyzed per PDE6 per sec) of PDE6 are ideally suited for 
the millisecond time-scale activation of PDE6 required for visual transduction, there 
appears to be little distinction in the active sites of the rod and cone isoforms as judged 
by this set of test compounds.
ICOS Rod IC50 Cone IC50 Selectivity ratio
compound (nM) (nM) (PDE6R/PDE6C)
Ai 205 ± 70 240 ± 40 0.9
a 2 320 ± 250 240± 150 1.3
a 3 1350 ±850 1200± 1300 1.8
Bi 650 ±350 1900± 1900 0.3
b 2 590± 100 660± 140 0.9
b 3 6150 ±3060 2550 ±730 2.4
b 4 59 ± 3 30 ± 4 1.8
C i 84 ± 15 70 ±40 1.6
c2 540 ± 320 380 ±230 1.4
c3 450 ±110 370 ±30 1.2
Table 3.1 PDE5 Inhibitor Ki Measurements on Rod PDE6 versus Cone PDE6. PDE5 
inhibitor compounds were supplied by ICOS with their molecular weight, chemical 
formula and structure, and were given arbitrary designations. IC50 values were 
determined as described in Fig. 3.1. The selectivity ratio was calculated as the ratio of the 
IC50 values for PDE6 R divided by PDE6 C. Data represent the average of two (or three)
experiments ± S.D.
B. Developing a Procedure for f3Hlvardenafil Binding to PDE6
3
Methods to lower nonspecific binding o f [  HJvardenafil during the membrane 
filtration binding assay—The radiolabeled PDE inhibitor [3H]vardenafil allows us to not 
only directly measure vardenafil binding affinity to PDE6 but also to assay whether the 
active sites are accessible. When we first attempted to use the filter binding conditions 
used for [3H]cGMP with PDE6 (Cote, 2005) or [3H]vardenafil with PDE5 (Blount et al.,
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2004), we observed very high nonspecific binding (30 times higher than a typical 
[ H]cGMP binding assay). This level of nonspecific binding obscures actual binding. 
Whereas the nonspecific binding for a typical [ H]cGMP filter binding assay is lower 
than 0.5% of the total DPMs under standard assay conditions (see Methods), greater than 
10% [3H]vardenafil (or [3H] sildenafil) DPMs were bound in the absence of PDE6.
In order to reduce this high nonspecific binding of [ H]vardenafil (or
'j
[ H] sildenafil), we first tested the washing solution used to rinse the membranes after 
applying the sample. The same amount of [ HJvardenafil as used for the binding assay 
was applied to pre-wetted filter membranes (Millipore 0.45 pm HA), then washed four 
times with 1 ml wash buffer (containing different additives). Figure 3.2 shows that 
increasing concentrations of salt did not lower the nonspecific binding effectively, nor 
did 1 mM EDTA. Detergent (0.1% Triton X-100) was found to be more useful in 
lowering nonspecific binding to about 25% of the total DPMs, but still higher than 
acceptable for accurate measurements of specific binding of [ Hjvardenafil (or 
[3H]sildenafil) to PDE6.
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Figure 3.2 Various Wash Buffers Tested to Reduce [3H]vardenafil Nonspecific 
Binding. [3H]vardenafil (176,000 DPM in a 50 pi volume) was directly applied onto pre­
wet mixed cellulose acetate filter membranes (Millipore 0.45 pm HA) under vacuum, and 
then washed 4 times with 1 ml of ice-cold 10 mM Tris buffer or buffer containing 0.1% 
Triton X-100, 1 mM EDTA, or 50 mM, 100 mM or 300 mM NaCl. The extent of 
[ Hjvardenafil nonspecific binding was then determined- by scintillation counting of the 
filters.
5
We assumed that the [ Hjvardenafil was adhering to the membrane support, so it 
seemed reasonable to test various types of membrane filters next. The results in Figure 
3.3 show that two types of glass fiber filters have the ability to lower the nonspecific 
binding of [3H]vardenafil, especially glass fiber #66075. Unfortunately, we were unable 
to use either type of glass fiber filter because of its inability to retain PDE6 on the filter 
during washing (data not shown). Since all other types of filter membranes showed a 
higher level of nonspecific binding, we continued to use the Millipore 0.45 pM HA 
membrane (routinely used for [ HJcGMP binding assay) for all subsequent experiments.
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Figure 3.3 Testing Different Types of Filter Membranes to Reduce [3H]vardenafil 
Nonspecific Binding. The following filter membranes were pre-wet under vacuum: 0.45 
pm HA (Millipore), 0.2 pm HT-20 (Gelman), 0.2 pm Supor-200 (Gelman), 0.45 pm T- 
450, Schleicher & Schuell #32 glass fiber filter 25 mm, or Gelman Sciences glass fiber 
filter 66075. After applying 50 pi portions of [3H]vardenafil (176,000 DPM) to each type 
of membrane, the membrane was washed 4 times with ice-cold 10 mM Tris (pH 7.5). The
-5
[ H]vardenafil nonspecific binding was then determined by scintillation counting of 
filters mixed with 4 ml Ultima Gold-XR.
We next tested the effect of pH on nonspecific drug binding. As Figure 3.4 shows, 
at the three pH values tested, about 80% of [3H]vardenafil was remained on the filter 
membrane after four washes. Wider ranges of pH were not tested, because of instability 
of PDE6 below pH 6.5 or above pH 8.5.
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Figure 3.4 Evaluating the effects of pH of the washing buffer on [3H]vardenafil 
nonspecific binding. [ Hjvardenafil (176,000 DPM in a 50 pi volume) was applied onto 
pre-wet filter membrane (Millipore 0.45 pm HA) under vacuum. The filters were washed 
by 4 times with 1 ml ice-cold 10 mM Tris (pH 7.5) adjusted to the following pH: 6.5, 7.5, 
or 8.5. The [3H]vardenafil nonspecific binding was then determined by scintillation 
counting.
We then speculated that varying the volume of the sample applied to the filter or 
the volume and number of washes could influence [ Hjvardenafil nonspecific binding. As 
showed in Figure 3.5, a larger, 1-ml sample volume is better than a 50 pi sample volume. 
In addition, 3 ml per wash is more effective than 1 ml of wash volume under all 
conditions tested for lowering the nonspecific binding. While at least four washes are 
needed to substantially reduce nonspecific binding, 6-8 washes are preferable to further 
reduce the nonspecific binding.
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From the previous experiments we conclude that the optimal conditions for 
lowering nonspecific binding for [ H]vardenafil (or [ H] sildenafil) to membrane filters 
were: (1) 0.1% Triton X-100 in wash buffer; (2) Increasing the 50 pi reaction volume to 1 
ml immediately before applying to the filter; (3) wash with 1 ml wash buffer 8 times. 
This method reduced the NSB to 3-5% of total DPMs and permitted us to quantify 
specific binding of radiolabeled inhibitors to PDE6.
o 15
50ul sam ple - 1ml wash■o
•“  10 50ul sam ple - 3ml wash
5 1ml sam ple -1m l wash
■— A
1ml sam ple - 3ml wash
2 4 6 8
N u m b e r o f w a s h e s
Figure 3.5 Effects of Sample Volume and Wash Number and Volume on 
[3H]vardenafil Nonspecific Binding. [3H]vardenafil (177,000 DPM per sample) was 
applied onto pre-wet filter membranes (Millipore 0.45 pM HA) under vacuum in a 
sample volume of 50 pi (circles) or 1 ml (triangles) and washed with either 1 ml (filled) 
or 3 ml (open) ice-cold 10 mM Tris (pH 7.5). The nonspecific binding on the filter 
membrane was qualified by scintillation counting.
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[sHjvardenafil binding is stabilized by a Py peptide during the filter binding 
assay—Although adding Triton X-100, increasing the sample volume, and increasing the 
filter washing successfully reduced the nonspecific binding to about 3-5% of total DPMs, 
initially we were unable to reliably detect [3H]vardenafil binding to PDE6 (i.e. no signal 
was detectible above the nonspecific binding). Therefore, histone II-AS was introduced 
into the binding solution (see Chapter 2) since it had been previously used in 
[3H]vardenafil binding assay of PDE5 (Blount et al., 2004). We also tested several other 
compounds, including PDE6-interacting compounds: histone VIII-S (Miki et al., 1975; 
Hurwitz et al., 1984), Py, and two Py peptides (Pyl-45 and Py63-87). The effects of 
histone VIII-S, Py, and Py63-87 on [ Hjvardenafil binding have already been described in 
Chapter 2. Surprisingly, Pyl-45, which is known to stabilize high affinity cGMP binding
-5
to the GAF domains (Mou and Cote, 2001), is also able to stabilize [ Hjvardenafil 
binding to the catalytic domains (Figure 3.6). There is no detected binding of vardenafil 
to PaB alone, but the binding was greatly enhanced by addition of histone II-AS or Pyl- 
45. The Pyl-45 stabilization of vardenafil binding to the catalytic site suggests an 
allosteric effect on the active site though GAF domain upon Py interaction with the GAF 
domain. The mechanism of action of histone II- AS is not clear.
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Figure 3.6 Comparison of [3H]vardenafiI Binding to PaB Stimulated by Histone II- 
AS or Pyl-45. Purified PaB (5 nM) and 70 nM [3H]vardenafil were incubated with 
histone II-AS (0.2 mg/ml) or Pyl-45 (10 pM) for 40 min at room temperature. Vardenafil 
binding was quantified by the membrane filtration assay. Data represents the average of
three experiments ± S.D.
Histone II-AS has minor effects on the catalysis o f PDE6 catalytic dimer, PDE6 
holoenzyme, and ROS membrane-associated PDE6—We tested the effect of histone II- 
AS on PDE6 catalysis, since we wanted to routinely use it to stabilize [3H]vardenafil 
inhibitor binding. While histone II-AS can dramatically increase the detectable vardenafil 
binding signal to catalytic sites of PaB (Figure 3.6), only minor effects were observed on 
PDE6 hydrolytic activity (when tested at the same concentration as used in the membrane 
filtration assay; Figure 3.7). Our results demonstrated that histone II-AS increased the 
basal activity of PDE6 holoenzyme to about 10 percent of its maximum value. 
Interestingly, histone II-AS can also decrease the catalysis of PaB by about 10 percent.
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Figure 3.7 Histone II-AS Effects on Trypsinized PDE6 and PDE6 Holoenzyme.
Increasing amounts of histone II-AS were incubated with trypsinized PDE6 (5 nM) or 
PDE6 holoenzyme (5 nM) for 10 min at room temperature. The catalytic activity was 
then determined by hydrolytic activity measurement using the phosphate release assay. 
Data represent one of three similar experiments.
We then further tested the histone II-AS effect on ROS-PDE6 in its trypsin- or 
transducin-activated state, and at the same histone II-AS concentration (0.2 mg/ml) we
•5
had used for [ Hjvardenafil binding to purified PDE6. We found that 0.2 mg/ml histone 
II-AS can increase about 30% the catalytic rate of transducin-activated PDE6. Because of 
this, we lowered the concentration of histone II-AS (0.05mg/ml) to test the effect on the 
catalysis of transducin-activated PDE6 as the GTPyS concentration was increased. Figure 
3.8 shows that transducin-activation of ROS-PDE6 is unaffected when 0.05 mg/ml 
histone II-AS is present. Although higher concentrations of histone II-AS can affect the 
extent of transducin activation, a low concentration of 0.05 mg/ml (suitable for 
[ Hjvardenafil binding assays) does not affect the catalytic properties of ROS-PDE6.
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These results suggest that histone II-AS not only may slow down the rapid exchange of 
radiolabeled inhibitor at the active site (useful for the binding assay), it may also decrease 
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Figure 3.8 Low Concentrations of Histone II-AS Do Not Affect the Catalytic 
Activity of Transducin-activated PDE6. Increasing concentrations of GTPyS were 
added to ROS homogenates (10 nM PDE6) to progressively activate PDE6. Then, 0.05 
mg/ml histone II-AS (filled circles) or buffer (open circles) was added, and the extent of 
PDE6 activation was quantified by measuring cGMP hydrolytic rates and normalized to 
the activity of the same sample fully activated by limited trypsin proteolysis.
Histone II-AS decreases the [  HJcGMP binding affinity to Pafi complexed with 
Pyl-45—In order to further explore the effects of histone II-AS on PDE6, we tested
•i
whether histone II-AS affected [ H]cGMP binding to the regulatory GAF domain. PDE6 
has two non-identical cGMP binding sites. One site can bind cGMP with high affinity in 
the absence of Py, while the other, low-affinity site requires Py to stabilize cGMP binding 
to the second site (Mou and Cote, 2001).
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Figure 3.9 Histone II-AS Lowers [3H]cGMP Binding to the Noncatalytic cGMP 
Binding Sites of PaB Reconstituted With Pyl-45. Nucleotide-depleted PaB (4 nM) was
incubated with the indicated concentration of histone II-AS along with buffer (filled 
circles), 10 pM Py (open circles), or 10 pM Pyl-45 (filled triangles) at 37°C for 5 min. 
[3H]cGMP (10 pM) was added for 5 min and binding quantified by the filter binding 
assay.
As expected, only one [3H]cGMP bound to PaB at its high affinity binding site; 
cGMP binding to PaB was unaltered by histone II-AS (Figure 3.9, filled circles). When 
Py or Pyl-45 was added 1.6 or 2.0 [3H]cGMP were bound per PDE6, confirming that the 
low affinity binding site was converted to a high affinity binding site (Figure 3.9). 
Histone II-AS did not significantly affect the binding of [3H]cGMP to PDE6 holoenzyme 
(PaPyy). However Pa(3 reconstituted with Pyl-45 showed a decrease in [3H]cGMP 
binding with increasing amounts of histone II-AS (Figure 3.9, triangles). These results 
suggest that histone II-AS may be able to compete with Pyl-45—but not full-length Py—
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in its binding to PaB, and that histone II-AS cannot by itself stabilize cGMP binding to
the low affinity binding site.
Anomalous effects o f histone VIII-S on PDE6 catalytic properties—Histone VIII- 
S, which historically has been used to activate PDE6 holoenzyme (Miki et al., 1975; 
Hurwitz et al., 1984), can stabilize vardenafil binding to a certain extent (see Chapter 2). 
We reexamined the effect of histone VIII-S on the catalysis of nonactivated PDE6 
holoenzyme or trypsinized PDE6, and surprisingly found that histone VIII-S was not able 
to activate PDE6 holoenzyme (Figure 3.10, filled circles). Also to our surprise, histone 
VIII-S can fully inhibit the catalysis of trypsinized PDE6 (Figure 3.10, open circles). The 
reasons for this unexpected behavior are not understood, but may reflect batch-to-batch 
variations in the histone VIII-S used in different labs.
Figure 3.10 Histone VIII-S Inhibits the Catalytic Activity of Trypsinized PDE6.
PDE6 holoenzyme (2.2 nM; filled circles) or trypsin-treated PDE6 (1.5 nM; open circles) 
was incubated with the indicated amounts of histone VIII-S, then PDE6 catalytic activity 
was measured and normalized to the maximum catalytic activity of PaB lacking histone
E
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9
[  H]sildenafil binds to PDE6 catalytic dimer lacking Py, but fails to bind to the 
holoenzyme—Radiolabeled inhibitors give us an unique opportunity to evaluate the
•5
catalytic sites of PDE6. As reported in Chapter 2, [ H] vardenafil binds to PDE6 catalytic 
dimer with high affinity (Kd = 7 nM) and Py blocks the access of Inhibitor binding to the 
active site. Consistent with this observation, [3H] sildenafil bound to PDE6 with high 
affinity (K d = 43 nM), in good agreement with the previously reported K; = 1 1  nM 
(Zhang et al., 2005). Furthermore, the binding curve was consistent with only one class of 
binding sites (Figure 3.11). Two sildenafil stoichiometrically bound to one PDE6 (Bmax = 
2.2) demonstrating that the catalytic sites of PDE6 are both available for sildenafil, which 
is in agreement with our conclusion from [ Hjvardenafil binding (Chapter 2). 
Furthermore, the simple hyperbolic behavior of drug binding suggests the two catalytic 
sites are identical. In contrast, sildenafil failed to bind to PDE6 when Pafi was 
reconstituted with Py, regardless of whether Py was added before or after [3H] sildenafil 
addition (Figure 3.11).
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Figure 3.11 [3H] sildenafil Binds Stoichiometrically to Each Pali Catalytic Subunit, 
But Only In the Absence of Py. Purified PaB (5 nM; filled circles) or PaB reconstituted 
with 10 pM Py was incubated with 0.2 mg/ml histone II-AS and 70 nM [3H] sildenafil 
(added after Py addition, squares; or before Py addition, triangles). Samples were 
incubated for 40 min before membrane filtration. Sildenafil binding was normalized to 
the PaB concentration, as estimated by both [3H]cGMP binding assay, as well as by 
hydrolytic activity measurements (which agreed to within 10%). [ H]sildenafil binding to 
PaB was fit assuming a single class of binding sites (KD = 42.9 nM and Bmax = 2.2). Data 
is representative of two experiments.
[3Hjvardenafil binds to ROS-PDE6 with lower affinity compared with highly 
purified PDE6—The experiments with highly purified PDE6 (above and in Chapter 2) 
concluded that two molecules of inhibitor can bind to each PaB heterodimer, but that 
binding is blocked when Py is associated with the catalytic dimer. We next tested the 
affinity of [3H]vardenafil for the catalytic sites under more physiological conditions, 
namely where PDE6 is still attached to the disk membrane in its trypsin- or transducin- 
activated states.
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Figure 3.12 shows that [3H]vardenafil binding to trypsin-activated ROS-PDE6 is 
consistent with a single class of binding sites with a lower apparent affinity than it binds 
to purified trypsinized PDE6. Under the conditions where Py inhibition was fully relieved 
on ROS-PDE6, the catalytic subunits bound 1.4 drug molecules per catalytic dimer. [The 
failure to reach the anticipated 2.0 mol drug per mol PDE6 was not readily explained.] 
No binding was detected with nonactivated ROS-PDE6 (data not shown) demonstrating 
that the highly specific drug molecules do not bind to other cellular components and that 
the Py subunit prevented inhibitor binding to catalytic sites on ROS-PDE6 as well. 
[ Hjvardenafil was also tested with ROS-PDE6 following transducin activation. The 
vardenafil binding to transducin-activated ROS-PDE6 (Figure 3.12, open circles) has a 
nearly 6-fold lower affinity compared with its binding to trypsin-activated ROS-PDE6 
(Figure 3.12, filled circles). Since the Py subunits were degraded by the trypsinization 
protocol, this lower apparent affinity of vardenafil for transducin-activated ROS-PDE6 
may be due to competition at the catalytic site between drug and Py which is displaced 
(but not completely dissociated) upon transducin activation.
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Figure 3.12 [3H]vardenafil Binds With Higher Affinity to Trypsinized ROS-PDE6 
than Transducin Activated ROS-PDE6. Trypsinized ROS homogenates (4 nM; filled 
circles) and transducin-activated ROS homogenates (10 nM; open circles) were incubated 
with 0.05 mg/ml histone II-AS and increasing concentrations of [3H]vardenafil. Samples 
were incubated for 40 min before membrane filtration. [3H]vardenafil binding to PDE6 
was fit assuming a single class of binding sites (trypsin-activated: K d = 20 nM, Bmax =1.4 
vardenafil per PDE6; transducin-activated: Kd = 112 nM, Bmax = 0.6 vardenafil per 
PDE6).
C. Allosteric Communication Between the Regulatory Domain and the Catalytic 
Site of PDE6
Drug binding at the catalytic site o f  PDE6 alters the cGMP binding properties to 
the GAF domain—Under the condition where there is no Py inhibition of the PaB active 
sites, cGMP can bind to one high affinity binding site (within the GAFa domain on PaB), 
as judged by a [3H]cGMP filter binding assay (Mou et al., 1999). Upon Py binding, a low 
affinity cGMP binding site undergoes a change from low affinity to high affinity, making 
the second cGMP binding to PDE6 detectable with the filter binding assay. In order to
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prevent the hydrolysis of cGMP at the catalytic sites, EDTA and/or PDE inhibitors were 
used to inhibit the catalytic activity during cGMP binding to the regulatory domain. We 
wished to examine whether the manner of inhibition of catalysis had an effect on cGMP 
binding to the GAF domain, since occupancy of the active site with drug might 
allosterically influence cGMP binding in a different manner than, for example, metal ion 
chelation at the active site.
Consistent with published work, 0.8 ±0.1 cGMP per PaB was detected when only 
EDTA was used to prevent the hydrolysis of cGMP, while 1.8 ± 0.1 cGMP bound per 
PDE6 catalytic dimer when Py was added back (Figure 3.13). The PDE inhibitors 
tadalafil and zaprinast showed similar results as EDTA, with only 1.0 - 1.4 cGMP per 
PDE6 in the absence of Py, and a stimulation of cGMP binding to about 2.0 mol cGMP 
per mol PDE6 upon Py addition. Surprisingly, the presence of sildenafil and vardenafil 
resulted in 1.8 ± 0.2 and 1.5 ± 0.1 [3H]cGMP bound per PaB in the absence of Py, with an 
insignificant increase in cGMP binding when Pot-P was reconstituted with Py. We further 
tested the stimulatory effect of sildenafil and vardenafil on cGMP binding to PaB by 
studying cGMP binding as a function of drug concentration (Figure 3.14). In general, the 
dose-response relationship for vardenafil and sildenafil is consistent with drug binding at 
the active site (and not some other binding site) being responsible for the stimulating 
action of these drugs on [3H]cGMP binding to the GAF domain. The enhanced binding of 
cGMP to the second class of lower affinity binding sites suggested that the second cGMP 
binding site undergoes a conformational change from low affinity to high affinity upon 
the occupancy of sildenafil or vardenafil at the active site.
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EDTA vardenafil sildenafil tadalafil zaprinast
Figure 3.13 Occupancy of the Catalytic Sites by Certain Inhibitors Alters the cGMP 
Binding to Regulatory GAF Domain. cGMP depleted, trypsinized PDE6 (3.7 nM) was 
treated with the following to prevent the hydrolysis of [3H]cGMP: 10 mM EDTA, 100 
pM vardenafil, 100 pM sildenafil, 100 pM tadalafil, or 100 pM zaprinast. Then, the 
inhibitor-treated PDE6 was mixed with 10 pM [3H]cGMP with buffer (black) or 10 pM 
Py (gray) and incubated at 37°C for 5 min before membrane filtration. Parallel 
measurements of PDE6 concentration were tested based on hydrolytic activity. Data are
the mean ± S.D. of two experiments.
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Figure 3.14 cGMP Binding to Regulatory GAF Domain is Enhanced by Vardenafil 
or Sildenafil In a Concentration Dependent Manner. cGMP-depleted trypsinized 
PDE6 was treated with the indicated concentration of vardenafil (filled circles) or 
sildenafil (open circles). Then the PDE6 was mixed with 10 pM [3H]cGMP and 
incubated at 37°C for 5 min before membrane filtration. PDE6 concentration was 
estimated based on its maximum hydrolytic activity (see Methods). [3H]cGMP binding to 
PDE6 was fit assuming a single class of binding sites (vardenafil: K 1/2 = 0.01 nM and 
Bmax = 1.6 CGMP/PDE6; sildenafil: K1/2 = 0.05 pM and Bmax -  2.0 cGMP/PDE6). Data 
represents one of two experiments.
PDE6 GAF domains may allosterically affect the catalytic site though Py subunits 
o f PDE6—As demonstrated in Section B, Pyl-45 was able to stabilize high affinity 
vardenafil binding when assayed in the absence of histone II-AS. This result suggested a 
direct allosteric effect between the GAF and catalytic domain. To further explore this 
phenomenon, we examined the concentration dependence of Pyl-45 stimulation. As 
shown in Figure 3.15, Pyl-45 is able to stabilize [3H]vardenafil binding to the catalytic 
domains in a concentration-dependent manner. A comparison of the dose-response
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curves shows that ~10-fold greater Pyl-45 is needed to enhance vardenafil binding 
compared to cGMP binding. This occurs over a range of Pyl-45 concentrations that have 
no direct effect on the hydrolytic activity at the catalytic domain (not shown). The greater 
potency of Pyl-45 to stimulate cGMP binding may be explained as a “local” stabilization 
of cGMP binding to the GAFa domain by Pyl-45 interaction with GAFa. In contrast, the 
lower potency of Pyl-45 to alter vardenafil binding may be explained as a more “distant” 
effect that requires conformational change be transmitted from the GAFa to the catalytic 
domain.
t  2 0a.
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Figure 3.15 Pyl-45 Stabilizes [3H]vardenafil and [3H]cGMP Binding to Pali 
Catalytic Subunits Over Different Concentration Ranges. Purified Pah (1 nM), 
[3H]vardenafil (70 nM; filled circles) and the indicated concentrations of Pyl-45 were 
incubated for 40 min before membrane filtration. Alternatively, cGMP-depleted, 
trypsinized PDE6  (6.7 nM final concentration) was first treated with 10 mM EDTA to 
prevent cGMP hydrolysis and then incubated with 10 pM [3H]cGMP and the indicated 
amount of Pyl-45 at 37°C for 5 min before membrane filtration (open circles). Vardenafil 
binding and cGMP binding were normalized to the PaB concentration, as estimated by 
hydrolytic activity measurements. [3H]vardenafil binding to Pafi was fit (2-parameter 
hyperbola) assuming a single class of binding sites (K4/2 = 1 . 4  pM and Bmax = 2.3 
cGMP/PDE6 ). [3H]cGMP binding data was fit to a 3-parameter hyperbolic function with 
K1/2 = 97 nM and Bmax = 2.0 cGMP per PDE6 . Note different scales for x-axis.
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Conclusion
■>
Through developing the filter binding assay for [ H]vardenafil to PDE6, we 
discovered that maximal binding required either histone II-AS or the N-terminal fragment 
of the inhibitory subunit of PDE6. There is no detected binding of vardenafil to PaB 
alone, but the binding was greatly enhanced by addition of certain peptides or proteins. 
While histone II-AS, histone VIII-S, Pyl-87 and Py63-87 can each stimulate somewhat 
vardenafil binding to PaB, only histone II-AS and Pyl-45 stabilize binding sufficiently so 
that both active sites of PaB can be labeled. The stimulation of drug binding at the active 
site by Pyl-45 demonstrated a direct allosteric communication between the GAF and 
catalytic domains. Pyl-45 is the N-terminal part of Py subunits that believed to bind only 
to the regulatory GAF domains of PDE6, and lacks contact sites with the catalytic 
domain (Guo et al., 2006). Thus, we propose that the enhancement of inhibitor binding 
within the catalytic domain is caused by the conformational change induced by Pyl-45 
binding to the regulatory GAF domains.
The function of histone II-AS is still unclear, but it might be the histone II-AS, 
which is polycationic, mimics the polycationic region of Pyl-45. Further work with 
chemically defined histones or peptides is needed to better define the mechanism of 
action of histone II-AS on PDE6 conformation.
66
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
FUTURE DIRECTIONS
One major conclusion of this thesis is that endogenous transducin can relieve Py 
inhibition at only one active site of PDE6, but that a second site can be detected when 
exogenous transducin is added to ROS membranes (Chapter 2). However, the current 
work failed to directly demonstrate the stoichiometry of transducin binding to PDE6. To 
address this question, cross-linking experiments could be performed. If the physical 
interaction site of PDE6 and transducin can be coupled successfully by the cross-linker, 
then native gel electrophoresis or size exclusion chromatography could be used to 
demonstrate whether one or two transducins bind per PDE6. For these experiments, both 
low and high concentrations of transducin would be needed to compare different 
interaction sites. A second approach to this question is to use analytical 
ultracentrifugation to determine the binding stoichiometry of transducin to PDE6. By 
detecting a shift in the sedimentation properties of labeled PDE6 when adding increasing 
amount of transducin, the added mass and/or changes in overall shape of the complex can 
be calculated.
This work also highlights the importance of membrane association of transducin 
and PDE6 for efficient activation of PDE6 during visual transduction (Chapter 2). Future 
experiments should be carried out to determine whether membrane binding alone or 
protein concentration on the membrane is the critical factor for efficient PDE6 activation 
by transducin. The composition of the membranes used for tethering transducin and
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PDE6  should also be examined; for example, are membrane vesicles prepared from 
purified phospholipids as effective as ROS membranes? If ROS membranes are more 
effective in stimulating PDE6  activation by transducin, then the identity of the 
stimulatory factors needs to be determined.
Another area that requires further study is the mechanism of action of histones on 
PDE6 . While our work suggests that histone II-AS competes with Py (particularly its 
polycationic region) for a common binding site on PDE6  catalytic dimer, the location of 
the interaction site, its affinity, and whether endogenous proteins (e.g., GARP2) may act 
similarly to histone II-AS, are all open questions. The ability of histone II-AS to stimulate 
drug binding (Chapters 2 and 3) is also not understood, and requires further work to 
determine whether histones exert a long-range effect via the GAF domains, or instead 
may bind directly to the catalytic domain to stabilize drug binding. Likewise, the effects 
of histone VIII-S we observe run counter to the published literature, and require further 
study to understand how this class of histone interacts with PDE6 .
Finally, further work is needed to determine the topology of the catalytic site of 
PDE6  and its ability to bind drugs in a selective manner. For example, compound B3 
(Chapter 3) shows selectivity of PDE6R compared to PDE5 (but no significant rod-cone 
selectivity). Analysis of additional inhibitor compounds may further delineate the subtle 
differences that distinguish PDE5 from PDE6 and rod PDE6 from cone PDE6.
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